CI Global Health Sciences Corporate Class

Series P USD
 

Fund overview

This fund invests primarily in equity and equity-related securities of companies around the world that specialize in the health care or medical industry.

Fund details

description of elementelement value
Inception date May 2017
CAD Total net assets ($CAD)
As at 2024-03-28
$147.1 million
NAVPS
As at 2024-05-01
$9.4957
MER (%)
As at 2023-09-30
0.24
Management fee (%) Negotiable
Asset class Sector Equity
Currency USD
Minimum investment $500 initial/$25 additional
Distribution frequency Quarterly
Last distribution $0.1669

Risk rating1

  • Low
  • Low to medium
  • Medium
  • Medium to high
  • High

FUND CODES

P 90324
A ISC 301
DSC SO* 401
LL SO 1401
F 324
*No new purchases directly into switch only funds.

Performance2 As at 2024-04-30

Growth of $10,000 (Since inception date)

growth of 10k graph

Calendar year performance

annual performance graph

average annual compound returns

YTD 1 Mo 3 Mo 6 Mo 1 Y 3 Y 5 Y 10 Y Inception*
3.17% -3.97% 1.93% 12.06% 7.12% -0.40% 6.31% - 6.10%
*Since inception date

Distribution history3

Payable date Total
2022-03-25 0.1669
2021-03-26 0.0563
2020-12-18 0.0892
2020-09-25 0.0844
2020-06-26 0.0615
Payable date Total
2020-03-20 0.1428
2019-12-13 0.0890
2019-09-27 0.0991
2019-06-21 0.0930
2019-03-22 0.1458

Management team

First we'll display the Team Company and then the Team members
Greg Quickmire
Peter Hofstra

CI Global Health Sciences Corporate Class

Series P USD
 
Portfolio allocations4 As at 2024-03-31
Asset allocation (%)
  • US Equity 79.07
  • International Equity 18.76
  • Cash and Equivalents 2.12
  • Other 0.05
Sector allocation (%)
  • Healthcare 92.77
  • Exchange Traded Fund 3.02
  • Cash and Cash Equivalent 2.12
  • Consumer Services 2.04
  • Other 0.05
Geographic allocation(%)
  • United States 81.02
  • United Kingdom 7.93
  • Denmark 7.76
  • Germany 3.13
  • Canada 0.08
  • Other 0.05
  • Switzerland 0.03
Top holdings
Sector (%)
1. Eli Lilly and Co Drugs 10.16%
2. UnitedHealth Group Inc Healthcare Services 9.63%
3. Novo Nordisk A/S Cl B Drugs 7.72%
4. Humana Inc Healthcare Services 7.01%
5. Merck & Co Inc Drugs 5.31%
6. AstraZeneca PLC Drugs 4.81%
7. AbbVie Inc Drugs 4.19%
8. Zoetis Inc Cl A Drugs 3.92%
9. Anthem Inc Healthcare Services 3.14%
10. Siemens Healthineers AG Healthcare Equipment 3.13%
11. Boston Scientific Corp Healthcare Equipment 3.10%
12. Gsk Plc Drugs 3.10%
13. Thermo Fisher Scientific Inc Healthcare Equipment 3.02%
14. SPDR S&P Biotech ETF (XBI) Exchange Traded Fund 3.02%
15. Stryker Corp Healthcare Equipment 3.01%
Over 35,000 financial advisors have chosen CI Global Asset Management as a partner. We believe that Canadians have the best opportunity for investments success by using the services of a professional financial advisor. Learn more at ci.com.